Expertise in
10
conditions

Dr. Radhika Gogoi

Oncology
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 
Expertise in
10
conditions
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 

Overview

Radhika Gogoi is an Oncologist practicing medicine in Detroit, Michigan.

Dr. Gogoi is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, Oophorectomy, and Salpingo-Oophorectomy.

She is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 17 clinical trials.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in NY

Hospital Affiliations

Karmanos Cancer Center
Harper University Hospital
Detroit Receiving Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Priority Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Karmanos Cancer Center
4100 John R St, Detroit, MI 48201
Other Locations
Supportive Care Services of Michigan Inc
400 Mack Ave, Detroit, MI 48201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
A Randomized, Double-Blind, Phase 3 Trial of Maintenance With Selinexor/ Placebo After Combination Chemotherapy for Patients With Advanced or Recurrent Endometrial Cancer
Enrollment Status: Completed
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer
Enrollment Status: Completed
Publish Date: November 13, 2025
Intervention Type: Other, Drug
Study Drugs: Letrozole, Paclitaxel, Pegylated liposomal doxorubicin hydrochloride, Tamoxifen citrate, Topotecan, Trametinib dimethyl sulfoxide
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
View 9 Less Clinical Trials

50 Total Publications

Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status.
Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status.
Journal: Gynecologic oncology
Published: September 26, 2025
Similar Doctors
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shirish Gadgeel is an Oncologist practicing medicine in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
31
conditions
Dr. Philip Philip
Oncology
Expertise in
31
conditions
Dr. Philip Philip
Oncology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (1.6 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Philip is an Oncologist practicing medicine in Detroit, Michigan. Dr. Philip is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Pancreatectomy, and Liver Embolization.

Expertise in
14
conditions
Dr. Elisabeth Heath
Oncology
Expertise in
14
conditions
Dr. Elisabeth Heath
Oncology

Karmanos Cancer Center

4100 John R St, 
Detroit, MI 
 (0.1 miles away)
313-576-8715
Languages Spoken:
English
See accepted insurances

Elisabeth Heath is an Oncologist practicing medicine in Detroit, Michigan. Dr. Heath is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Frequently Asked Questions about Dr. Radhika Gogoi

How do I make an appointment with Dr. Radhika Gogoi?

You can book an appointment with Dr. Radhika Gogoi by calling their office at 800-527-6266. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Radhika Gogoi a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Radhika Gogoi is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Radhika Gogoi specialize in?

While Dr. Radhika Gogoi is a Oncology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Testicular Yolk Sac Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Radhika Gogoi participate in research or clinical trials?

Yes. Dr. Radhika Gogoi has published 50 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Radhika Gogoi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Radhika Gogoi accept my insurance?

Dr. Radhika Gogoi accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 800-527-6266 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gogoi's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile